ARTICLE | Management Tracks
Rezo names Nazir Mahmood CEO
Plus: Bendtsen named CEO of Orphazyme, and updates from Acadia, OM1 and BioPorto
September 20, 2023 9:12 PM UTC
Disease-mapping company Rezo Therapeutics Inc. named Nadir Mahmood as CEO and a director. Mahmood, who was chief financial and business officer of Nkarta Inc. (NASDAQ:NKTX), succeeds co-founder and interim CEO Nevan Krogan, who remains president.
Jakob Bendtsen will succeed Anders Fink Vadsholt as CEO of Orphazyme A/S (CSE:ORPHA), effective Oct. 1. Bendtsen will continue to serve on the board of the company, which is now part of Zevra Therapeutics Inc. (NASDAQ:ZVRA)...